Thursday, August 11, 2016 8:07 PM
|
CCSVI in Multiple Sclerosis
This headline is a lie---earlier treatment of MS w/interferon made NO DIFFERENCE in disability or MS progression. Bayer Pharmaceutical sponsored the study. "There was no difference between the two groups in the tests that measure overall disability or in MRI scans measuring the amount of damage caused by the disease." Starting medication for multiple sclerosis (MS) in people who show the beginning signs of the disease is associated with prolonging the time before the disease is definitively diagnosed, according to a long-term study published in the Aug. 10, 2016, online issue of Neurology®, the medical journal of...
|